nodes	percent_of_prediction	percent_of_DWPC	metapath
Tazarotene—Facial pain—Capecitabine—esophageal cancer	0.0241	0.154	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.0224	0.0265	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.0224	0.0265	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors—NR1I2—esophageal cancer	0.0205	0.0243	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.0201	0.0238	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.0201	0.0238	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.0199	0.0236	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.0192	0.0228	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.0192	0.0228	CbGpPWpGaD
Tazarotene—RARG—Vitamin A and Carotenoid Metabolism—CYP26A1—esophageal cancer	0.0185	0.022	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors—NR1I2—esophageal cancer	0.0184	0.0218	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.0179	0.0212	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—NR1I2—esophageal cancer	0.0176	0.0209	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—NR1I2—esophageal cancer	0.0176	0.0209	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.0172	0.0203	CbGpPWpGaD
Tazarotene—RARB—Vitamin A and Carotenoid Metabolism—CYP26A1—esophageal cancer	0.0166	0.0197	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptor transcription pathway—NR1I2—esophageal cancer	0.0162	0.0192	CbGpPWpGaD
Tazarotene—RARA—Vitamin A and Carotenoid Metabolism—CYP26A1—esophageal cancer	0.016	0.0189	CbGpPWpGaD
Tazarotene—RXRB—Vitamin A and Carotenoid Metabolism—CYP26A1—esophageal cancer	0.016	0.0189	CbGpPWpGaD
Tazarotene—RARG—Vitamin A and Carotenoid Metabolism—CRABP1—esophageal cancer	0.0158	0.0187	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptor transcription pathway—NR1I2—esophageal cancer	0.0145	0.0172	CbGpPWpGaD
Tazarotene—RARB—Vitamin A and Carotenoid Metabolism—CRABP1—esophageal cancer	0.0141	0.0168	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—NR1I2—esophageal cancer	0.0139	0.0165	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—NR1I2—esophageal cancer	0.0139	0.0165	CbGpPWpGaD
Tazarotene—Localised oedema—Capecitabine—esophageal cancer	0.0138	0.0886	CcSEcCtD
Tazarotene—RXRB—Vitamin A and Carotenoid Metabolism—CRABP1—esophageal cancer	0.0136	0.0161	CbGpPWpGaD
Tazarotene—RARA—Vitamin A and Carotenoid Metabolism—CRABP1—esophageal cancer	0.0136	0.0161	CbGpPWpGaD
Tazarotene—Localized exfoliation—Capecitabine—esophageal cancer	0.013	0.0831	CcSEcCtD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—SFN—esophageal cancer	0.0123	0.0146	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.0106	0.0125	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.0095	0.0113	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.0091	0.0108	CbGpPWpGaD
Tazarotene—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—esophageal cancer	0.00841	0.00997	CbGpPWpGaD
Tazarotene—CYP2C8—CYP2E1 reactions—CYP2A6—esophageal cancer	0.00809	0.00958	CbGpPWpGaD
Tazarotene—RARG—Retinoic acid receptors-mediated signaling—CREBBP—esophageal cancer	0.00782	0.00927	CbGpPWpGaD
Tazarotene—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—esophageal cancer	0.00765	0.00907	CbGpPWpGaD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—BCL2—esophageal cancer	0.00756	0.00896	CbGpPWpGaD
Tazarotene—RARB—Retinoic acid receptors-mediated signaling—CREBBP—esophageal cancer	0.00701	0.00831	CbGpPWpGaD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—BCL2—esophageal cancer	0.00678	0.00804	CbGpPWpGaD
Tazarotene—RARA—Retinoic acid receptors-mediated signaling—CREBBP—esophageal cancer	0.00672	0.00797	CbGpPWpGaD
Tazarotene—RXRB—Retinoic acid receptors-mediated signaling—CREBBP—esophageal cancer	0.00672	0.00797	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—CYP26A1—esophageal cancer	0.00658	0.0078	CbGpPWpGaD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—BCL2—esophageal cancer	0.0065	0.0077	CbGpPWpGaD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—BCL2—esophageal cancer	0.0065	0.0077	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.00633	0.00751	CbGpPWpGaD
Tazarotene—Leukoderma—Methotrexate—esophageal cancer	0.00613	0.0392	CcSEcCtD
Tazarotene—Hypertriglyceridaemia—Capecitabine—esophageal cancer	0.00609	0.039	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.00607	0.0072	CbGpPWpGaD
Tazarotene—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.00588	0.0376	CcSEcCtD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—MET—esophageal cancer	0.00557	0.0066	CbGpPWpGaD
Tazarotene—Blood triglycerides increased—Capecitabine—esophageal cancer	0.00534	0.0342	CcSEcCtD
Tazarotene—RARG—Retinoic acid receptors-mediated signaling—EP300—esophageal cancer	0.00533	0.00631	CbGpPWpGaD
Tazarotene—CYP2C8—Xenobiotics—CYP2A6—esophageal cancer	0.00501	0.00594	CbGpPWpGaD
Tazarotene—Pain—Carboplatin—esophageal cancer	0.00494	0.0316	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.00492	0.00583	CbGpPWpGaD
Tazarotene—Blister—Capecitabine—esophageal cancer	0.00485	0.031	CcSEcCtD
Tazarotene—CYP2C8—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00482	0.00571	CbGpPWpGaD
Tazarotene—RARB—Retinoic acid receptors-mediated signaling—EP300—esophageal cancer	0.00478	0.00566	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.00472	0.00559	CbGpPWpGaD
Tazarotene—RXRB—Retinoic acid receptors-mediated signaling—EP300—esophageal cancer	0.00458	0.00543	CbGpPWpGaD
Tazarotene—RARA—Retinoic acid receptors-mediated signaling—EP300—esophageal cancer	0.00458	0.00543	CbGpPWpGaD
Tazarotene—Skin exfoliation—Cisplatin—esophageal cancer	0.00453	0.029	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.00438	0.028	CcSEcCtD
Tazarotene—RXRB—Regulation of Androgen receptor activity—CREBBP—esophageal cancer	0.00427	0.00506	CbGpPWpGaD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—ERBB2—esophageal cancer	0.00407	0.00483	CbGpPWpGaD
Tazarotene—CYP2C8—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00389	0.00461	CbGpPWpGaD
Tazarotene—Skin discolouration—Capecitabine—esophageal cancer	0.00387	0.0248	CcSEcCtD
Tazarotene—Burning sensation—Methotrexate—esophageal cancer	0.00375	0.024	CcSEcCtD
Tazarotene—Inflammation—Capecitabine—esophageal cancer	0.00361	0.0231	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.00334	0.00396	CbGpPWpGaD
Tazarotene—Skin exfoliation—Capecitabine—esophageal cancer	0.00334	0.0214	CcSEcCtD
Tazarotene—CYP2C8—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00329	0.0039	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.00321	0.0038	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.00306	0.00362	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.00293	0.00347	CbGpPWpGaD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00292	0.00346	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.00291	0.00345	CbGpPWpGaD
Tazarotene—RXRB—Regulation of Androgen receptor activity—EP300—esophageal cancer	0.0029	0.00344	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.0029	0.00344	CbGpPWpGaD
Tazarotene—Skin discolouration—Methotrexate—esophageal cancer	0.00288	0.0184	CcSEcCtD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00288	0.00342	CbGpPWpGaD
Tazarotene—Swelling—Capecitabine—esophageal cancer	0.00288	0.0184	CcSEcCtD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—esophageal cancer	0.00282	0.00335	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—NR1I2—esophageal cancer	0.0028	0.00331	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.00279	0.00331	CbGpPWpGaD
Tazarotene—Inflammation—Methotrexate—esophageal cancer	0.00268	0.0172	CcSEcCtD
Tazarotene—Dermatitis bullous—Capecitabine—esophageal cancer	0.00266	0.017	CcSEcCtD
Tazarotene—RARA—Adipogenesis—HIF1A—esophageal cancer	0.00255	0.00302	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00255	0.00302	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—NR1I2—esophageal cancer	0.00251	0.00297	CbGpPWpGaD
Tazarotene—Skin exfoliation—Methotrexate—esophageal cancer	0.00249	0.0159	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.00246	0.00292	CbGpPWpGaD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—PIK3CA—esophageal cancer	0.00245	0.0029	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—NR1I2—esophageal cancer	0.0024	0.00285	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—NR1I2—esophageal cancer	0.0024	0.00285	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.00239	0.00283	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.00239	0.00283	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00237	0.00281	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.00236	0.0028	CbGpPWpGaD
Tazarotene—Dry skin—Capecitabine—esophageal cancer	0.00233	0.0149	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.00229	0.00271	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.00229	0.00271	CbGpPWpGaD
Tazarotene—CYP2C8—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.00228	0.00271	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.00226	0.00268	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.00217	0.00257	CbGpPWpGaD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00208	0.00247	CbGpPWpGaD
Tazarotene—Erythema—Cisplatin—esophageal cancer	0.00207	0.0133	CcSEcCtD
Tazarotene—RARA—Adipogenesis—RB1—esophageal cancer	0.00207	0.00246	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00205	0.00243	CbGpPWpGaD
Tazarotene—Photosensitivity reaction—Capecitabine—esophageal cancer	0.002	0.0128	CcSEcCtD
Tazarotene—CYP2C8—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.00194	0.0023	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00179	0.00213	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—SMG6—esophageal cancer	0.00178	0.0021	CbGpPWpGaD
Tazarotene—Haemoglobin—Capecitabine—esophageal cancer	0.00177	0.0113	CcSEcCtD
Tazarotene—Haemorrhage—Capecitabine—esophageal cancer	0.00176	0.0112	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.00176	0.00208	CbGpPWpGaD
Tazarotene—Discomfort—Cisplatin—esophageal cancer	0.00175	0.0112	CcSEcCtD
Tazarotene—Oedema peripheral—Capecitabine—esophageal cancer	0.00173	0.0111	CcSEcCtD
Tazarotene—Oedema—Cisplatin—esophageal cancer	0.00169	0.0108	CcSEcCtD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00169	0.002	CbGpPWpGaD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00168	0.00199	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00166	0.00196	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.0016	0.0019	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.0016	0.0019	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.0016	0.00189	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—SMG6—esophageal cancer	0.00159	0.00189	CbGpPWpGaD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00158	0.00187	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.00157	0.00187	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.00157	0.00187	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00156	0.00185	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—ADH7—esophageal cancer	0.00154	0.00183	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.00154	0.00182	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.00153	0.00181	CbGpPWpGaD
Tazarotene—Erythema—Capecitabine—esophageal cancer	0.00153	0.00978	CcSEcCtD
Tazarotene—RXRB—Gene Expression—SMG6—esophageal cancer	0.00153	0.00181	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—SMG6—esophageal cancer	0.00153	0.00181	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.00151	0.00179	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.00151	0.00179	CbGpPWpGaD
Tazarotene—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00149	0.00954	CcSEcCtD
Tazarotene—RARA—Adipogenesis—CDKN1A—esophageal cancer	0.00149	0.00177	CbGpPWpGaD
Tazarotene—Pain—Cisplatin—esophageal cancer	0.00145	0.00926	CcSEcCtD
Tazarotene—RARB—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.00141	0.00167	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.00138	0.00163	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00136	0.00161	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.00135	0.0016	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.00135	0.0016	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—ADH1B—esophageal cancer	0.00135	0.0016	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—NR1I2—esophageal cancer	0.00135	0.0016	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.00134	0.00158	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—SMAD4—esophageal cancer	0.00132	0.00157	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.00132	0.00156	CbGpPWpGaD
Tazarotene—Haemoglobin—Methotrexate—esophageal cancer	0.00131	0.00841	CcSEcCtD
Tazarotene—Haemorrhage—Methotrexate—esophageal cancer	0.00131	0.00837	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.00131	0.00155	CbGpPWpGaD
Tazarotene—Discomfort—Capecitabine—esophageal cancer	0.00129	0.00823	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.00128	0.00152	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00128	0.00152	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP26A1—esophageal cancer	0.00126	0.00149	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.00125	0.00148	CbGpPWpGaD
Tazarotene—Oedema—Capecitabine—esophageal cancer	0.00125	0.00798	CcSEcCtD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00124	0.00147	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—NR1I2—esophageal cancer	0.00121	0.00143	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—SMAD4—esophageal cancer	0.00119	0.00141	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	0.00118	0.0014	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—GSTO1—esophageal cancer	0.00117	0.00139	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—NR1I2—esophageal cancer	0.00116	0.00137	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—NR1I2—esophageal cancer	0.00116	0.00137	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—HIST1H2BM—esophageal cancer	0.00115	0.00137	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—GSTO1—esophageal cancer	0.00115	0.00137	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	0.00114	0.00135	CbGpPWpGaD
Tazarotene—Erythema—Methotrexate—esophageal cancer	0.00114	0.00728	CcSEcCtD
Tazarotene—RARA—Generic Transcription Pathway—SMAD4—esophageal cancer	0.00114	0.00135	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—SMAD4—esophageal cancer	0.00114	0.00135	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	0.00113	0.00134	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	0.00109	0.0013	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	0.00109	0.00129	CbGpPWpGaD
Tazarotene—Rash—Cisplatin—esophageal cancer	0.00107	0.00683	CcSEcCtD
Tazarotene—Pain—Capecitabine—esophageal cancer	0.00107	0.00683	CcSEcCtD
Tazarotene—Dermatitis—Cisplatin—esophageal cancer	0.00107	0.00682	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	0.00104	0.00123	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—HIST1H2BM—esophageal cancer	0.00104	0.00123	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—HIST1H2BM—esophageal cancer	0.000993	0.00118	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—HIST1H2BM—esophageal cancer	0.000993	0.00118	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000974	0.00116	CbGpPWpGaD
Tazarotene—Discomfort—Methotrexate—esophageal cancer	0.000958	0.00613	CcSEcCtD
Tazarotene—CYP2C8—Biological oxidations—ALDH2—esophageal cancer	0.000953	0.00113	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.000947	0.00112	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.000926	0.0011	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.000908	0.00108	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—GSTT1—esophageal cancer	0.000907	0.00107	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP2A6—esophageal cancer	0.000896	0.00106	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—PSME1—esophageal cancer	0.000896	0.00106	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—PSME2—esophageal cancer	0.000896	0.00106	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.000888	0.00105	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000884	0.00105	CbGpPWpGaD
Tazarotene—Pruritus—Capecitabine—esophageal cancer	0.000883	0.00565	CcSEcCtD
Tazarotene—CYP2C8—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000875	0.00104	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000874	0.00104	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—PTGS1—esophageal cancer	0.00085	0.00101	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—NOTCH3—esophageal cancer	0.000845	0.001	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000838	0.000993	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000838	0.000993	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.000804	0.000953	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PSME2—esophageal cancer	0.000803	0.000952	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PSME1—esophageal cancer	0.000803	0.000952	CbGpPWpGaD
Tazarotene—Pain—Methotrexate—esophageal cancer	0.000795	0.00508	CcSEcCtD
Tazarotene—RARB—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000792	0.000939	CbGpPWpGaD
Tazarotene—Rash—Capecitabine—esophageal cancer	0.000787	0.00503	CcSEcCtD
Tazarotene—Dermatitis—Capecitabine—esophageal cancer	0.000786	0.00503	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.000778	0.000922	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.000771	0.000913	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PSME1—esophageal cancer	0.00077	0.000913	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PSME1—esophageal cancer	0.00077	0.000913	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PSME2—esophageal cancer	0.00077	0.000913	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PSME2—esophageal cancer	0.00077	0.000913	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—CREBBP—esophageal cancer	0.00076	0.000901	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—CREBBP—esophageal cancer	0.00076	0.000901	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—NOTCH3—esophageal cancer	0.000758	0.000898	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—NOTCH2—esophageal cancer	0.000758	0.000898	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.000745	0.000884	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—NOTCH3—esophageal cancer	0.000727	0.000861	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—NOTCH3—esophageal cancer	0.000727	0.000861	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP1B1—esophageal cancer	0.000722	0.000856	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000713	0.000845	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000697	0.000826	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—NOTCH2—esophageal cancer	0.00068	0.000806	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP19A1—esophageal cancer	0.000679	0.000805	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00067	0.000794	CbGpPWpGaD
Tazarotene—Pruritus—Methotrexate—esophageal cancer	0.000657	0.0042	CcSEcCtD
Tazarotene—RXRB—Gene Expression—NOTCH2—esophageal cancer	0.000652	0.000773	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—NOTCH2—esophageal cancer	0.000652	0.000773	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—SMAD4—esophageal cancer	0.000636	0.000754	CbGpPWpGaD
Tazarotene—Rash—Methotrexate—esophageal cancer	0.000586	0.00375	CcSEcCtD
Tazarotene—Dermatitis—Methotrexate—esophageal cancer	0.000585	0.00374	CcSEcCtD
Tazarotene—RARB—Gene Expression—SMAD4—esophageal cancer	0.000571	0.000677	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—SMAD4—esophageal cancer	0.000547	0.000649	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—SMAD4—esophageal cancer	0.000547	0.000649	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—MYC—esophageal cancer	0.000524	0.000622	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000471	0.000558	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—MYC—esophageal cancer	0.00047	0.000557	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—NOTCH1—esophageal cancer	0.000469	0.000556	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—MYC—esophageal cancer	0.000451	0.000534	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—MYC—esophageal cancer	0.000451	0.000534	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—CREBBP—esophageal cancer	0.000425	0.000504	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—NOTCH1—esophageal cancer	0.000421	0.000499	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000411	0.000487	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—NOTCH1—esophageal cancer	0.000403	0.000478	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—NOTCH1—esophageal cancer	0.000403	0.000478	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—CREBBP—esophageal cancer	0.000382	0.000452	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—CREBBP—esophageal cancer	0.000366	0.000434	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—CREBBP—esophageal cancer	0.000366	0.000434	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—BLVRB—esophageal cancer	0.000365	0.000433	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SLC52A3—esophageal cancer	0.000365	0.000433	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000326	0.000387	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CA1—esophageal cancer	0.00031	0.000368	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SLC10A2—esophageal cancer	0.00031	0.000368	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CA2—esophageal cancer	0.000284	0.000336	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000277	0.000329	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PLCE1—esophageal cancer	0.000264	0.000313	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ADH7—esophageal cancer	0.000264	0.000313	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000261	0.000309	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—MYC—esophageal cancer	0.000252	0.000299	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ADH1B—esophageal cancer	0.000231	0.000274	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—MYC—esophageal cancer	0.000226	0.000268	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TYMP—esophageal cancer	0.000221	0.000262	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—MYC—esophageal cancer	0.000217	0.000257	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—MYC—esophageal cancer	0.000217	0.000257	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP26A1—esophageal cancer	0.000215	0.000255	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ALOX15—esophageal cancer	0.00021	0.000248	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTO1—esophageal cancer	0.0002	0.000237	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TPI1—esophageal cancer	0.0002	0.000237	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ALDOB—esophageal cancer	0.000192	0.000227	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GAPDH—esophageal cancer	0.000185	0.000219	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CRABP1—esophageal cancer	0.000183	0.000217	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GNG7—esophageal cancer	0.000174	0.000206	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ALDH2—esophageal cancer	0.000163	0.000193	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GSTT1—esophageal cancer	0.000155	0.000184	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP2A6—esophageal cancer	0.000153	0.000182	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000153	0.000181	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ENO1—esophageal cancer	0.000145	0.000172	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PTGS1—esophageal cancer	0.000145	0.000172	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PSME1—esophageal cancer	0.000143	0.00017	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PSME2—esophageal cancer	0.000143	0.00017	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000125	0.000148	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP1B1—esophageal cancer	0.000124	0.000146	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP19A1—esophageal cancer	0.000116	0.000138	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—HMOX1—esophageal cancer	0.000106	0.000126	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000104	0.000123	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ABCB1—esophageal cancer	0.000102	0.000121	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.69e-05	9.12e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CREBBP—esophageal cancer	6.8e-05	8.06e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NOS3—esophageal cancer	6.09e-05	7.22e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PTGS2—esophageal cancer	5.57e-05	6.6e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—EP300—esophageal cancer	4.63e-05	5.49e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PIK3CA—esophageal cancer	3.43e-05	4.06e-05	CbGpPWpGaD
